Steven Leonard Chapman, CEO and President of Natera, Inc. (NASDAQ:NTRA), recently executed a series of stock transactions, according to a filing with the Securities and Exchange Commission. On October 21 and 22, Chapman sold a total of 2,602 shares of Natera's common stock, valued at approximately $313,597. The shares were sold at prices ranging from $120.07 to $120.7575 per share.
These sales were conducted to satisfy tax withholding obligations related to the vesting of restricted stock units (RSUs). Following these transactions, Chapman retains direct ownership of 193,722 shares of Natera's common stock.
In other recent news, Natera, Inc. has secured a permanent injunction against NeoGenomics (NASDAQ:NEO)' RaDaR assay, following a preliminary injunction in December 2023. The court ruling is a significant development in Natera's ongoing efforts to protect its intellectual property rights within the genetic testing market. In financial news, Natera reported a 12% sequential revenue increase from the first quarter and a 58% surge year-over-year. Piper Sandler, TD Cowen, and Canaccord Genuity have maintained positive stances on Natera, reiterating their price targets and Buy ratings. These ratings are based on the forthcoming Galaxy study results and Natera's presentation at the European Society for Medical Oncology conference, which includes significant data from the CIRCULATE-Japan and GALAXY trials. Natera's Renasight test has also received an endorsement from the National Kidney Foundation for chronic kidney disease testing. Despite a delay in the submission of the ALTAIR study and the non-renewal of the Foundation Medicine partnership, Natera is projecting a 40% revenue growth compared to 2023. These recent developments underscore Natera's commitment to growth and innovation in the personalized genetic testing and diagnostics space.
InvestingPro Insights
Adding context to Steven Leonard Chapman's recent stock transactions, Natera, Inc. (NASDAQ:NTRA) has been experiencing significant market momentum. According to InvestingPro data, the company's stock has shown a remarkable 199.28% price total return over the past year, with a 31.76% increase in the last six months alone. This robust performance aligns with the company's strong revenue growth, which stood at 46.13% for the last twelve months as of Q2 2024.
Despite the impressive stock performance, InvestingPro Tips highlight that Natera is not currently profitable, with analysts not anticipating profitability this year. This insight provides valuable context to Chapman's decision to sell shares for tax purposes, as it's common for executives to manage their stock holdings in growth-stage companies that are reinvesting heavily in expansion.
The company's market capitalization of $14.87 billion USD reflects investor optimism about Natera's future prospects. However, it's worth noting that the stock is trading at a high Price / Book multiple of 17.73, suggesting that investors are pricing in significant future growth expectations.
For readers seeking a more comprehensive analysis, InvestingPro offers 11 additional tips for Natera, providing a deeper understanding of the company's financial health and market position.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.